This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-09-1642v1 69/20/7895    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Ménétrier-Caux, C. Articles by Caux, C. PubMed PubMed Citation Articles by Ménétrier-Caux, C. Articles by Caux, C. Related Collections Tumor Biology Tumor Biology: Inflammation and Immune Escape Cancer Immunology: Adaptive Immunity

Differences in Tumor Regulatory T-Cell Localization and Activation Status Impact Patient Outcome

¹ Inserm, U590, ² Centre Léon Bérard, Equipe Cytokines et Cancers, ³ Université Lyon 1, ISPB, and ⁴ IFR62, Lyon, France

Requests for reprints: Christine Ménétrier-Caux, Centre Léon Bérard, Equipe Cytokines et Cancers, Inserm, U590, Lyon, F-69008, France. Phone: 4-78-78-27-20; Fax: 4-78-78-27-50; E-mail: caux{at}lyon.fnclcc.fr.

The presence of regulatory T cells (Treg) has been described in a large panel of solid tumors. However, their impact on tumor progression differs according to the tumor type analyzed. We recently obtained evidence in breast carcinoma that Treg localized within lymphoid aggregates, but not in the tumor bed, have a negative impact on patients' survival. Moreover, we showed selective Treg recruitment through CCR4/CCL22 in the lymphoid aggregates upon contact with dendritic cells (DC), where they became strongly and selectively activated (ICOS^high) and block conventional T-cell response. Here, we discuss the meaning and potential implication of these novel findings. [Cancer Res 2009;69(20):7895–8]